JP2017507943A - Ｈｅｒ２／ｎｅｕ過剰発現腫瘍の治療のための組成物および方法 - Google Patents

Ｈｅｒ２／ｎｅｕ過剰発現腫瘍の治療のための組成物および方法 Download PDF

Info

Publication number
JP2017507943A
JP2017507943A JP2016553897A JP2016553897A JP2017507943A JP 2017507943 A JP2017507943 A JP 2017507943A JP 2016553897 A JP2016553897 A JP 2016553897A JP 2016553897 A JP2016553897 A JP 2016553897A JP 2017507943 A JP2017507943 A JP 2017507943A
Authority
JP
Japan
Prior art keywords
another embodiment
her2
neu
tumor
listeria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016553897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507943A5 (enExample
Inventor
バファ シャハビ，
バファ シャハビ，
アヌ ワレチャ，
アヌ ワレチャ，
パウロ シー． マシアグ，
パウロ シー． マシアグ，
イボンヌ パターソン，
イボンヌ パターソン，
二コラ メイソン，
二コラ メイソン，
マシュー シーベイ，
マシュー シーベイ，
Original Assignee
アドバクシス， インコーポレイテッド
アドバクシス， インコーポレイテッド
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/189,008 external-priority patent/US20150366955A9/en
Priority claimed from US14/268,436 external-priority patent/US20140234370A1/en
Application filed by アドバクシス， インコーポレイテッド, アドバクシス， インコーポレイテッド, ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア, ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア filed Critical アドバクシス， インコーポレイテッド
Publication of JP2017507943A publication Critical patent/JP2017507943A/ja
Publication of JP2017507943A5 publication Critical patent/JP2017507943A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016553897A 2014-02-25 2015-02-25 Ｈｅｒ２／ｎｅｕ過剰発現腫瘍の治療のための組成物および方法 Pending JP2017507943A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14/189,008 2014-02-25
US14/189,008 US20150366955A9 (en) 2009-11-11 2014-02-25 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US14/268,436 2014-05-02
US14/268,436 US20140234370A1 (en) 2009-11-11 2014-05-02 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US201462076411P 2014-11-06 2014-11-06
US62/076,411 2014-11-06
PCT/US2015/017559 WO2015130810A2 (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors

Publications (2)

Publication Number Publication Date
JP2017507943A true JP2017507943A (ja) 2017-03-23
JP2017507943A5 JP2017507943A5 (enExample) 2018-08-02

Family

ID=54009773

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016553897A Pending JP2017507943A (ja) 2014-02-25 2015-02-25 Ｈｅｒ２／ｎｅｕ過剰発現腫瘍の治療のための組成物および方法

Country Status (12)

Country Link
EP (1) EP3110942A4 (enExample)
JP (1) JP2017507943A (enExample)
KR (2) KR20160122829A (enExample)
CN (1) CN106661538A (enExample)
AU (1) AU2015223136A1 (enExample)
BR (1) BR112016019534A2 (enExample)
CA (1) CA2940646A1 (enExample)
IL (1) IL247436A0 (enExample)
MX (1) MX2016011114A (enExample)
RU (1) RU2016137834A (enExample)
SG (1) SG11201607036XA (enExample)
WO (1) WO2015130810A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
WO2012125551A1 (en) 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
AU2013232291B8 (en) 2012-03-12 2016-07-21 Advaxis, Inc. Suppressor cell function inhibition following listeria vaccine treatment
EP3107566A4 (en) 2014-02-18 2017-10-11 Advaxis, Inc. Biomarker directed multi-target immunotherapy
BR112016020364A2 (pt) * 2014-03-05 2018-01-16 Advaxis, Inc. métodos para suscitar uma resposta de uma célula t antitumoral em um indivíduo tendo um tumor ou câncer e para aumentar a razão de células t efetoras sobre células t reguladoras no baço de um indivíduo
CA2946716A1 (en) 2014-04-24 2015-10-29 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
SG11201804957VA (en) 2015-12-16 2018-07-30 Gritstone Oncology Inc Neoantigen identification, manufacture, and use
SG11201901979SA (en) 2016-11-30 2019-04-29 Advaxis Inc Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
US11179339B2 (en) 2017-09-19 2021-11-23 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or listeria strains
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
KR20200090855A (ko) 2017-11-22 2020-07-29 그릿스톤 온콜로지, 인코포레이티드 신생항원에 대한 접합 에피토프 제시 감소

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013025925A1 (en) * 2011-08-16 2013-02-21 Advaxis Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855320B2 (en) * 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013025925A1 (en) * 2011-08-16 2013-02-21 Advaxis Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
JP6039669B2 (ja) * 2011-08-16 2016-12-07 アドバクシス インコーポレイテッド Ｈｅｒ２／ｎｅｕ発現腫瘍に対する薬剤の調製における弱毒化組換えリステリアの使用

Also Published As

Publication number Publication date
WO2015130810A3 (en) 2016-01-28
BR112016019534A2 (pt) 2017-10-24
EP3110942A4 (en) 2017-08-30
EP3110942A2 (en) 2017-01-04
AU2015223136A1 (en) 2016-09-22
IL247436A0 (en) 2016-11-30
NZ723750A (en) 2024-02-23
KR20240038103A (ko) 2024-03-22
CA2940646A1 (en) 2015-09-03
CN106661538A (zh) 2017-05-10
KR20160122829A (ko) 2016-10-24
RU2016137834A (ru) 2018-03-29
SG11201607036XA (en) 2016-09-29
WO2015130810A2 (en) 2015-09-03
MX2016011114A (es) 2017-02-20

Similar Documents

Publication Publication Date Title
AU2022200643B2 (en) Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof
JP6039669B2 (ja) Ｈｅｒ２／ｎｅｕ発現腫瘍に対する薬剤の調製における弱毒化組換えリステリアの使用
JP2017507943A (ja) Ｈｅｒ２／ｎｅｕ過剰発現腫瘍の治療のための組成物および方法
US20160361401A1 (en) Compositions and methods for the treatment of her2/neu over-expressing tumors
US10016617B2 (en) Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
JP5985397B2 (ja) 組換えリステリア株およびそれを含む免疫原性組成物
US10695410B2 (en) Compositions comprising angiogenic factors and methods of use thereof
AU2013232291B2 (en) Suppressor cell function inhibition following listeria vaccine treatment
US10143734B2 (en) Biomarker directed multi-target immunotherapy
US20150297702A1 (en) Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
JP2017514904A (ja) Ｈｅｒ２陽性ガンの治療のための免疫療法および放射線療法の併用
JP6329211B2 (ja) 脳腫瘍または乳腺腫瘍の発症を遅延させるための医薬の製造における組換えリステリア株の使用
TW201707715A (zh) 用於治療ｈｅｒ－２陽性癌症之組合免疫療法及放射線療法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190913